Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has "little or no effect" on death rates among hospitalized patients. 

Remdesivir has ‘little or no effect' in reducing coronavirus deaths, WHO says

A clinical trial conducted by the World Health Organization found that Gilead Sciences Inc.'s remdesivir, hydroxychloroquine, AbbVie's lopinavir/ritonavir and interferon did not impact mortality among hospitalized COVID-19 patients. The study was first reported by the Financial Times on Thursday.

Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy, as a potential treatment for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton's tyrosi

European CHMP Adopts Positive Opinion for Kite's KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces complex insurance reimbursement issues.

Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint

Gilead Sciences, Inc.'s (NASDAQ: GILD) antiviral drug remdesivir has been found to have "little or no effect on mortality on hospitalized COVID-19," a global study conducted by the World Health Organization has concluded. The study is posted on a pre-print server and is yet to be peer-reviewed.

Gilead's Remdesivir Ineffective In COVID-19 Patients, WHO Study Finds

Albertsons Companies

American Well Corporation

Dollar General

Home Depot

NIKE

Sociedad Quimica Y Minera De Chile

Smith & Wesson Brands

Wheaton Precious Metals

With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.

9 Stocks to Buy for a Wild Ride in October

A clinical trial reportedly found that Gilead Sciences Inc.'s COVID-19 treatment remdesivir had no impact on survival in patients with the coronavirus, according to a report in the Financial Times.

Remdesivir didn't reduce mortality among COVID-19 in WHO study: Report

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2020 financial results will be released on Wednesday, October 28, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s third quarter 2020 financial results and will provide a business update. The live webcast of the call can be accessed at the company’s Investors page at investors.gilead.com. Please connect to t

Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020

Gilead is a major pharmaceutical company that has become a leader in antiviral

Gilead: Incredible Antivirals, Risky Drug Lineup

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Immunomedics, Inc. expired at 11:59 p.m. on October 13, 2020. On September 25, 2020, Gilead and Immunomedics filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer

Gilead Sciences (GILD) closed at $64.49 in the latest trading session, marking a -0.09% move from the prior day.

Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know

Galapagos

Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.

Gilead & Galapagos Announce Positive Data on UC Candidate

Ford Motor Company

General Electric

International Paper

With stocks close to all-time highs again, many investors have missed out on the great stock market recovery of 2020.

6 Unpopular Stocks That Scored Major Analyst Upgrades Ahead of Earnings

Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.

Gilead Up on Positive Final Results for Coronavirus Treatment

Alexion Pharma

Amgen

Biogen

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for September 30, the most recent settlement date.

Short Sellers Need to Find a Clue on Major Biotechs

Best Buy

Pacer US Cash Cows 100 ETF

CVS Health

Discovery

Intel

Kroger

Lennar

Altria

Target

Tyson Foods

One way to find undervalued stocks is to use free cash flow yield as a barometer. Here are 10 stocks to buy based on this criterion.

10 Undervalued Stocks to Buy From the Pacer US Cash Cows 100 ETF

FOSTER CITY, Calif., & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis (UC). The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantl

Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the novel Coronavirus – is up by 16% year-to-date, compared to the S&P 500 which is up about 4%. While the long-term demand for Covid-19 treatments is not clear.

Regeneron & Gilead: Covid Treatment Stocks Back In Focus As Winter Nears

Neurocrine Biosciences

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

4 Very Profitable Biotech Stocks Expected to Soar Into 2021

Gilead Sciences, Inc. (NASDAQ: GILD) shares were trading higher Friday after the company announced the publication of final results from the Phase 3, NIAID-sponsored trial of Veklury in adults hospitalized with mild-to-moderate COVID-19.

Gilead's Veklury Study Shows Faster COVID-19 Recovery, Reduced Disease Progression, Mortality

Gilead will have enough global supply of its coronavirus treatment remdesivir by the end of October, CEO Daniel O'Day told CNBC on Friday.

Gilead CEO: 'We have ample supply' of remdesivir for hospitalized coronavirus patients

Gilead Sciences Inc. GILD said late Thursday that a late-stage study of its experimental COVID-19 treatment showed it shortened time to recovery. The company said a study of remdesivir, which goes by the trade name Veklury, plus standard of care shortened the time of recovery by an average four days, compared with a placebo and standard of care.

Gilead study shows drug speeds up COVID-19 recovery

FOSTER CITY, Calif.--(BUSINESS WIRE)--The New England Journal of Medicine (NEJM) today published the final results from the National Institute of Allergy and Infectious Diseases’ (NIAID) double-blind, placebo-controlled, Phase 3 ACTT-1 trial of Gilead’s (Nasdaq: GILD) investigational antiviral Veklury® (remdesivir) for the treatment of adults hospitalized with mild-moderate or severe COVID-19. The final ACTT-1 study results build on the preliminary results published in NEJM in May 2020, showing

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

AbbVie

Enterprise Products Partners

Ingredion

Urstadt Biddle Properties

5 Dividend Stocks That Remain Good Buys In This Roller Coaster Market

Deal with European Commission comes amid a surge in COVID-19 cases across Europe.

News for Gilead Sciences Stock (GILD)